Anzeige
Mehr »
Login
Donnerstag, 06.05.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Halo Collective setzt neue Meilensteine!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0EAT9 ISIN: BE0003818359 Ticker-Symbol: GXE 
Tradegate
05.05.21
21:26 Uhr
63,83 Euro
-0,53
-0,82 %
1-Jahres-Chart
GALAPAGOS NV Chart 1 Jahr
5-Tage-Chart
GALAPAGOS NV 5-Tage-Chart
RealtimeGeldBriefZeit
63,9964,2105.05.
63,9264,1005.05.

Aktuelle News zur GALAPAGOS NV Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
GALAPAGOS NV Aktie jetzt für 0€ handeln
DiGalapagos NV: Transparency notification received from The Capital Group148Mechelen, Belgium; 4 May 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc. Pursuant...
► Artikel lesen
FrGalapagos NV: Galapagos creates new subscription right plans266Mechelen, Belgium; 30 April 2021, 22.01 CET; regulated information -- Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its supervisory board created 2,736,250 subscription rights...
► Artikel lesen
23.04.e-Therapeutics gets two payments from Galapagos under collaboration16
23.04.E-therapeutics to receive two milestone payments from Galapagos2
23.04.e-Therapeutics plc: ETX to receive two payments from Galapagos1
23.04.Galapagos NV: Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies422Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis Mechelen, Belgium; 23 April 2021; 06.01 CET; - Galapagos...
► Artikel lesen
14.04.ANALYSE-FLASH: Barclays hebt Galapagos auf 'Overweight' und Ziel auf 80 Euro376LONDON (dpa-AFX Broker) - Die britische Investmentbank Barclays hat Galapagos von "Equal Weight" auf "Overweight" hochgestuft und das Kursziel von 69 auf 80 Euro angehoben. Bei den Aktien des belgischen...
► Artikel lesen
09.04.GALAPAGOS NV - 6-K, Report of foreign issuer9
08.04.Gilead-Galapagos extends lock-up period for collaboration50
08.04.Galapagos NV: Extension of lock-up period in Gilead-Galapagos collaboration agreement660Mechelen, Belgium; 08 April 2021; 22.01 CET; Galapagos (Euronext & Nasdaq; GLPG) announced today that Gilead and Galapagos signed an amendment to the share subscription agreement closed in 2019...
► Artikel lesen
25.03.Galapagos NV: Publication of the annual report and invitation to the ordinary shareholders' meeting464Mechelen, Belgium; 25 March 2021; 21.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2020. The annual report for the financial...
► Artikel lesen
24.03.Galapagos NV: Galapagos appoints Bart Filius as President and Chief Operating Officer453Mechelen, Belgium; 24 March 2021; 21.01 CET; Galapagos (Euronext & Nasdag; GLPG) announced today that its Supervisory Board has promoted Bart Filius to President and Chief Operating Officer (COO). Going...
► Artikel lesen
23.03.Galapagos May Finally Get Around Its CRL Situation29
19.03.Galapagos NV: Galapagos increases share capital through subscription right exercises1.203Mechelen, Belgium; 19 March 2021, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos...
► Artikel lesen
04.03.Galapagos posts a safety win for filgotinib, but is it too little, too late?; Bio-Techne inks $320M molecular diagnostics buyout50
04.03.Galapagos' Filgotinib Shows Interim Safety In Ongoing Studies15
04.03.GALAPAGOS NV - 6-K, Report of foreign issuer5
04.03.Galapagos reports interim filgotinib data from MANTA AND MANTA-RAy studies14
04.03.Galapagos NV: GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES3658.3% patients on placebo and 6.7% patients on filgotinib had a 50% or more decline in sperm concentration at week 13No new safety findings were identifiedData will be submitted to the relevant...
► Artikel lesen
03.03.Galapagos NV: Transparency notification received from The Capital Group860Mechelen, Belgium; 3 March 2021; 22.15 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc. Pursuant...
► Artikel lesen
Seite:  Weiter >>
98 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,10